ASHP -- BETHESDA, MD 24 June 2009—A patient advocacy group’s campaign and the media’s recent focus on generic drug substitution have increased the need for pharmacists to judge FDA-declared bioequivalent products by more than just price, say two pharmacists who work at epilepsy clinics.
